HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating for Silence Therapeutics (NASDAQ:SLN) and maintained a price target of $75.
August 30, 2024 | 9:44 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a Buy rating for Silence Therapeutics, maintaining a $75 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $75 price target by a reputable analyst suggests positive sentiment and potential upside for Silence Therapeutics. This could lead to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100